Table 4 Treatment is displayed for each year in the 10-year period from 2004 to 2013 for patients with rheumatoid arthritis monitored with outcome measures in an ordinary outpatient clinic

No treatment^a

44 (10.9)

102 (16.9)

94 (15.2)

110 (14.8)

99 (12.4)

139 (14.3)

122 (11.4)

121 (11.0)

132 (11.9)

106 (9.8)

0.45

Biologic DMARDs (%)

141 (34.9)

170 (28.1)

161 (26.0)

203 (27.3)

234 (29.4)

265 (27.3)

335 (31.3)

342 (31.0)

366 (32.9)

373 (34.4)

0.30

TNF inhibitor

139 (34.4)

170 (28.1)

159 (25.6)

176 (23.7)

192 (24.1)

198 (20.4)

236 (22.1)

221 (20.0)

230 (20.7)

227 (21.0)

0.70

Non-TNF inhibitors

2 (0.5)

0 (0)

2 (0.3)

27 (3.6)

42 (5.3)

67 (6.9)

99 (9.3)

121 (11.0)

136 (12.2)

146 (13.5)

0.016

Synthetic DMARDs (%)

267 (66.1)

349 (58.8)

351 (56.6)

440 (59.2)

471 (59.2)

562 (58.0)

627 (58.7)

667 (60.5)

668 (60.0)

660 (60.9)

0.73

 One synthetic DMARD (%)

243 (60.1)

321 (53.1)

342 (55.2)

423 (56.9)

455 (57.2)

547 (56.4)

612 (57.2)

648 (58.7)

649 (58.3)

649 (59.9)

0.88

 Two synthetic DMARDs (%)

24 (5.9)

28 (4.6)

9 (1.5)

16 (2.2)

16 (2.0)

14 (1.4)

14 (1.3)

18 (1.6)

17 (1.5)

10 (0.9)

 Three synthetic DMARDs (%)

0 (0)

0 (0)

0 (0)

1 (0.1)

0 (0)

1 (0.1)

1 (0.1)

1 (0.1)

2 (0.2)

1 (0.1)

Biologic and synthetic DMARDs

100 (24.8)

123 (20.4)

114 (18.4)

142 (19.1)

155 (19.5)

176 (18.2)

216 (20.2)

226 (20.5)

234 (21.0)

233 (21.5)

0.58

TNF inhibitor and synthetic DMARDs

99 (24.5)

123 (20.4)

113 (18.2)

129 (17.4)

132 (16.6)

145 (15.0)

167 (15.6)

170 (15.4)

170 (15.3)

162 (15.0)

0.94

Prednisolone (%)

224 (55.4)

334 (55.3)

369 (59.5)

433 (58.3)

486 (61.1)

589 (60.8)

653 (61.1)

653 (59.2)

617 (55.4)

590 (54.5)

0.005

Prednisolone and synthetic DMARDs (%)

152 (37.6)

208 (34.4)

216 (34.8)

270 (36.3)

297 (37.3)

354 (36.5)

377 (35.3)

394 (35.7)

368 (33.1)

346 (31.9)

0.43

Biologic DMARD and prednisolone

53 (13.1)

61 (10.1)

57 (9.2)

78 (10.5)

90 (11.3)

101 (10.4)

125 (11.7)

125 (11.3)

124 (11.1)

120 (11.1)

0.80

Biologic DMARDs

 Adalimumab (%)

27 (6.7)

50 (8.3)

51 (8.2)

56 (7.5)

58 (7.3)

80 (8.3)

78 (7.3)

70 (6.3)

61 (5.5)

52 (4.8)

0.08

 Certolizumab (%)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

8 (0.7)

10 (0.9)

21 (1.9)

44 (4.1)

0.000

 Etanercept (%)

60 (14.9)

77 (12.7)

68 (11.0)

73 (9.8)

96 (12.1)

88 (9.1)

98 (9.2)

109 (9.9)

118 (10.6)

104 (9.6)

0.72

 Golimumab (%)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

26 (2.4)

14 (1.3)

12 (1.1)

9 (0.8)

0.008

 Infliximab (%)

52 (12.9)

43 (7.1)

40 (6.5)

47 (6.3)

38 (4.8)

30 (3.1)

26 (2.4)

18 (1.6)

18 (1.6)

18 (1.7)

0.42

 Abatacept (%)

0 (0)

0 (0)

0 (0)

3 (0.4)

3 (0.4)

5 (0.5)

11 (1.0)

21 (1.9)

23 (2.1)

15 (1.4)

0.19

 Anakinra (%)

2 (0.5)

0 (0)

1 (0.2)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

–

 Rituximab (%)

0 (0)

0 (0)

1 (0.2)

24 (3.2)

39 (4.9)

58 (6.0)

76 (7.1)

88 (8.0)

102 (9.2)

118 (10.9)

0.013

 Tocilizumab (%)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

4 (0.4)

12 (1.1)

12 (1.1)

11 (1.0)

13 (1.2)

0.97

Synthetic DMARDs

 Leflunomide (%)

15 (3.7)

31 (5.1)

29 (4.7)

40 (5.4)

44 (5.5)

55 (5.7)

63 (5.9)

64 (5.8)

62 (5.6)

58 (5.4)

0.95

 Methotrexate (%)

212 (52.5)

269 (44.5)

275 (44.4)

349 (47.0)

360 (45.2)

438 (45.2)

496 (46.4)

544 (49.3)

558 (50.1)

551 (50.9)

0.17

 Methotrexate dose weekly (mg)

10.0 (2.3)

10.2 (2.7)

10.6 (2.6)

10.8 (2.8)

11.3 (3.0)

11.9 (3.0)

12.3 (3.4)

12.6 (3.4)

13.2 (3.6)

13.5 (3.8)

<0.001

 Sulfasalazine (%)

12 (3.0)

20 (3.3)

21 (3.4)

27 (3.6)

31 (3.9)

31 (3.2)

39 (3.6)

36 (3.3)

32 (2.9)

39 (3.6)

0.73

 Hydroxychloroquine (%)

37 (9.2)

42 (7.0)

24 (3.9)

30 (4.0)

35 (4.4)

39 (4.0)

36 (3.4)

35 (3.2)

31 (2.8)

20 (1.8)

0.14

 Other synthetic DMARDs^b (%)

15 (3.7)

15 (2.5)

11 (1.8)

11 (1.5)

16 (2.0)

14 (1.4)

9 (0.8)

7 (0.6)

5 (0.4)

3 (0.3)

0.32